Immunotherapies hold enormous promise for treating cancers of various types, but the bad news is that while many patients may initially respond many will also become resistant. Valsamo Anagnostou, a cancer researcher at Johns Hopkins, is looking at tumor specific …
Published on 1 week, 2 days ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate